-
How many women in your family planning facility may be missing a needed Pap smear? Check your numbers: One-fourth of uninsured U.S. women between the ages of 18-64 report not having had a Pap smear within the last three years of a government-issued survey.
-
New research released on Lybrel, the first dedicated continuous use oral contraceptive (OC) (Wyeth Pharmaceuticals; Collegeville, PA), underscores the safety of the new drug.
-
If your practice includes older women, what is your approach in discussing risks for HIV? It's time to address such issues. Results of a new study indicate that older women may not be interested in being tested for HIV, despite having significant risk factors for lifetime exposure.
-
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV.
-
Your next patient says she is interested in using Lybrel, the new continuous-use oral contraceptive (OC). What should you tell her about this form of birth control?
-
Your next patient is a young mother of three who is looking for long-term, effective contraception. She says she is not ready to consider tubal sterilization. What methods can you offer her?
-
Take that vision and expand it a thousandfold, as evidenced by the New York City Department of Health and Mental Hygiene's new NYC Condom.
-
To obtain up-to-the-minute education on intrauterine contraception, attend A Clinical Update on Intrauterine Contraception continuing medical education program organized by the Association of Reproductive Health Professionals (ARHP).
-
The next patient in your exam room is an 18-year-old female. What do you think she knows about intrauterine contraception?
-
A year after the Food and Drug Administration (FDA) approved behind-the-counter status for the emergency contraceptive (EC) pill Plan B (Barr Pharmaceuticals; Pomona, NY) is the drug more available to women? While the company says sales have increased from about $40 million annually to an expected $80 million for 2007, availability is mixed, according to reports around the country.